Show simple item record

dc.contributor.authorCharlton, Rachel A
dc.contributor.authorKlungsøyr, Kari
dc.contributor.authorNeville, Amanda J
dc.contributor.authorJordan, Sue
dc.contributor.authorPierini, Anna
dc.contributor.authorde Jong-van den Berg, Lolkje T W
dc.contributor.authorBos, H Jens
dc.contributor.authorPuccini, Aurora
dc.contributor.authorEngeland, Anders
dc.contributor.authorGini, Rosa
dc.contributor.authorDavies, Gareth
dc.contributor.authorThayer, Daniel
dc.contributor.authorHansen, Anne V
dc.contributor.authorMorgan, Margery
dc.contributor.authorWang, Hao
dc.contributor.authorMcGrogan, Anita
dc.contributor.authorAndersen, Anne-Marie Nybo
dc.contributor.authorDolk, Helen
dc.contributor.authorGarne, Ester
dc.date.accessioned2016-07-05T11:38:06Z
dc.date.available2016-07-05T11:38:06Z
dc.date.issued2016-05-18
dc.identifier.citationPLoS ONE 2016, 11(5)eng
dc.identifier.urihttp://hdl.handle.net/1956/12269
dc.description.abstractAim: To explore antidiabetic medicine prescribing to women before, during and after pregnancy in different regions of Europe. Methods: A common protocol was implemented across seven databases in Denmark, Norway, The Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK. Women with a pregnancy starting and ending between 2004 and 2010, (Denmark, 2004–2009; Norway, 2005–2010; Emilia Romagna, 2008–2010), which ended in a live or stillbirth, were identified. Prescriptions for antidiabetic medicines issued (UK) or dispensed (non-UK) during pregnancy and/or the year before or year after pregnancy were identified. Prescribing patterns were compared across databases and over calendar time. Results: 1,082,673 live/stillbirths were identified. Pregestational insulin prescribing during the year before pregnancy ranged from 0.27% (CI95 0.25–0.30) in Tuscany to 0.45% (CI95 0.43–0.47) in Norway, and increased between 2004 and 2009 in all countries. During pregnancy, insulin prescribing peaked during the third trimester and increased over time; third trimester prescribing was highest in Tuscany (2.2%) and lowest in Denmark (0.5%). Of those prescribed an insulin during pregnancy, between 50.5% in Denmark and 88.8% in the Netherlands received an insulin analogue alone or in combination with human insulin, this proportion increasing over time. Oral products were mainly metformin and prescribing was highest in the 3 months before pregnancy. Metformin use during pregnancy increased in some countries. Conclusion: Pregestational diabetes is increasing in many areas of Europe. There is considerable variation between and within countries in the choice of medication for treating pregestational diabetes in pregnancy, including choice of insulin analogues and oral antidiabetics, and very large variation in the treatment of gestational diabetes despite international guidelines.eng
dc.language.isoengeng
dc.publisherPublic Library of Scienceeng
dc.relation.urihttp://journals.plos.org/plosone/article/asset?id=10.1371%2Fjournal.pone.0155737.PDF
dc.rightsThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.titlePrescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regionseng
dc.typeJournal articleeng
dc.date.updated2016-05-19T10:45:51Z
dc.rights.holderCopyright 2016 Charlton et al.eng
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
dc.type.documentJournal article
dc.identifier.cristinID1356280
dc.identifier.doi10.1371/journal.pone.0155737eng
dc.source.issn1932-6203eng
noa.nsiVDP::Medisinske Fag: 700::Helsefag: 800eng


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.